Decitabine

The role of MRD status & the ELN 2022 in predicting clinical outcomes of patients with AML 1:23
The role of MRD status & the ELN 2022 in predicting clinical outcomes of patients with AML
Eunice Wang • 12 Dec 2022
Exciting updates in higher-risk MDS at ASH 2022 1:27
Exciting updates in higher-risk MDS at ASH 2022
Valeria Santini • 12 Dec 2022
STIMULUS-MDS1: Phase II study of sabatolimab added to HMAs in high-risk MDS 1:30
STIMULUS-MDS1: Phase II study of sabatolimab added to HMAs in high-risk MDS
Uwe Platzbecker • 9 Dec 2022
Decitabine, venetoclax and ponatinib in patients with advanced CML and Ph+ AML 1:17
Decitabine, venetoclax and ponatinib in patients with advanced CML and Ph+ AML
Jayastu Senapati • 11 Nov 2022
Phase I trial investigating CD8-depleted HLA-mismatched unrelated DLI in patients with MDS and AML 4:18
Phase I trial investigating CD8-depleted HLA-mismatched unrelated DLI in patients with MDS and AML
Hany Elmariah • 11 Dec 2022
How the AML treatment landscape is changing with the introduction of novel targeted agents 5:25
How the AML treatment landscape is changing with the introduction of novel targeted agents
Francesco Lanza • 24 Oct 2022
Low-dose azacitidine and venetoclax as maintenance therapy in patients with AML 2:27
Low-dose azacitidine and venetoclax as maintenance therapy in patients with AML
Tapan Kadia • 29 Sep 2022
AML in 2022 and beyond 1:35
AML in 2022 and beyond
Amir Fathi • 22 Sep 2022
CMML: unmet needs and future outlooks 1:10
CMML: unmet needs and future outlooks
Eric Padron • 26 Aug 2022
Highlights in AML and MDS from EHA 2022 3:02
Highlights in AML and MDS from EHA 2022
Shai Shimony • 13 Jun 2022
Highlights in AML: quizartinib in elderly patients & in frontline FLT3-mutated AML 0:51
Highlights in AML: quizartinib in elderly patients & in frontline FLT3-mutated AML
Tapan Kadia • 10 Jun 2022
The current state of the art in HR-MDS and the need to improve treatment approaches 1:06
The current state of the art in HR-MDS and the need to improve treatment approaches
Uwe Platzbecker • 21 Jun 2022
A Phase I/II study evaluating quizartinib plus decitabine and venetoclax in FLT3-mutated AML 4:03
A Phase I/II study evaluating quizartinib plus decitabine and venetoclax in FLT3-mutated AML
Musa Yilmaz • 31 May 2022
Updates from a study evaluating ASTX727 + venetoclax for patients with AML 4:20
Updates from a study evaluating ASTX727 + venetoclax for patients with AML
Tareq Abuasab • 30 Jun 2022
Maintenance therapy in AML 2:03
Maintenance therapy in AML
Tapan Kadia • 10 Jun 2022
Lower-intensity frontline therapy for newly diagnosed AML 1:44
Lower-intensity frontline therapy for newly diagnosed AML
Tapan Kadia • 10 Jun 2022
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals